U.S. Food, 2020-06-30: Second joint FDA/FTC warning letter, naming methylene blue capsules among products sold with COVID-19 treatment claims and declaring them unapproved new drugs.
The FDA has observed that your website offers a “COVID Supplement Protection Pack” (also referred to as the “COVID Household Value Pack”), Thymosin-Alpha, and Methylene Blue Capsules for sale in the United States and that these products are intended to mitigate, prevent, treat, diagnose, or cure COVID-19 [1] in people.
Warning letter, body paragraph 1
U.S. Food, 2020-06-30: Second joint FDA/FTC warning letter, naming methylene blue capsules among products sold with COVID-19 treatment claims and declaring them unapproved new drugs. Opened and quoted; HTML-only publication, so pdf_url blank (not guessed). Reviewed website drtomyarema.com (FTC review 17 June 2020, FDA review 25 June 2020). Same statutory basis, 21 U.S.C. 355(a). Note for the record: the letters address marketing claims, not the safety of methylene blue as a drug , the product is FDA-approved for methemoglobinemia (ProvayBlue), which the letters do not dispute. Also filed as MTO-60, MTD-054 (claims C10, C9). Study type: regulatory record.
